Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
Non-small cell lung cancer (NSCLC) is the most common lung cancer diagnosis, among which epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (KRAS), and anaplastic lymphoma kinase (ALK) mutations are the common genetic drivers. Their relative tyrosine kinase inhibitors (TKIs) have shown a b...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1094764/full |
| _version_ | 1811159603314950144 |
|---|---|
| author | Shanshan Chen Jingyi Tang Fen Liu Wei Li Ting Yan Dangang Shangguan Nong Yang Dehua Liao |
| author_facet | Shanshan Chen Jingyi Tang Fen Liu Wei Li Ting Yan Dangang Shangguan Nong Yang Dehua Liao |
| author_sort | Shanshan Chen |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is the most common lung cancer diagnosis, among which epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (KRAS), and anaplastic lymphoma kinase (ALK) mutations are the common genetic drivers. Their relative tyrosine kinase inhibitors (TKIs) have shown a better response for oncogene-driven NSCLC than chemotherapy. However, the development of resistance is inevitable following the treatments, which need a new strategy urgently. Although immunotherapy, a hot topic for cancer therapy, has shown an excellent response for other cancers, few responses for oncogene-driven NSCLC have been presented from the existing evidence, including clinical studies. Recently, the tumor microenvironment (TME) is increasingly thought to be a key parameter for the efficacy of cancer treatment such as targeted therapy or immunotherapy, while evidence has also shown that the TME could be affected by multi-factors, such as TKIs. Here, we discuss changes in the TME in NSCLC after TKI treatments, especially for EGFR-TKIs, to offer information for a new therapy of oncogene-driven NSCLC. |
| first_indexed | 2024-04-10T05:44:03Z |
| format | Article |
| id | doaj.art-36f6e74b29df45748b908c92054a5c4e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T05:44:03Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-36f6e74b29df45748b908c92054a5c4e2023-03-06T04:41:39ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.10947641094764Changes of tumor microenvironment in non-small cell lung cancer after TKI treatmentsShanshan Chen0Jingyi Tang1Fen Liu2Wei Li3Ting Yan4Dangang Shangguan5Nong Yang6Dehua Liao7Department of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaDepartment of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaDepartment of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaDepartment of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaDepartment of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaDepartment of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaLung Cancer and Gastrointestinal Unit, Department of Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaDepartment of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaNon-small cell lung cancer (NSCLC) is the most common lung cancer diagnosis, among which epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (KRAS), and anaplastic lymphoma kinase (ALK) mutations are the common genetic drivers. Their relative tyrosine kinase inhibitors (TKIs) have shown a better response for oncogene-driven NSCLC than chemotherapy. However, the development of resistance is inevitable following the treatments, which need a new strategy urgently. Although immunotherapy, a hot topic for cancer therapy, has shown an excellent response for other cancers, few responses for oncogene-driven NSCLC have been presented from the existing evidence, including clinical studies. Recently, the tumor microenvironment (TME) is increasingly thought to be a key parameter for the efficacy of cancer treatment such as targeted therapy or immunotherapy, while evidence has also shown that the TME could be affected by multi-factors, such as TKIs. Here, we discuss changes in the TME in NSCLC after TKI treatments, especially for EGFR-TKIs, to offer information for a new therapy of oncogene-driven NSCLC.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1094764/fullnon-small cell lung cancerdriver mutationtyrosine kinase inhibitortumor microenvironmentICIs - immune checkpoint inhibitors |
| spellingShingle | Shanshan Chen Jingyi Tang Fen Liu Wei Li Ting Yan Dangang Shangguan Nong Yang Dehua Liao Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments Frontiers in Immunology non-small cell lung cancer driver mutation tyrosine kinase inhibitor tumor microenvironment ICIs - immune checkpoint inhibitors |
| title | Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments |
| title_full | Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments |
| title_fullStr | Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments |
| title_full_unstemmed | Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments |
| title_short | Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments |
| title_sort | changes of tumor microenvironment in non small cell lung cancer after tki treatments |
| topic | non-small cell lung cancer driver mutation tyrosine kinase inhibitor tumor microenvironment ICIs - immune checkpoint inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1094764/full |
| work_keys_str_mv | AT shanshanchen changesoftumormicroenvironmentinnonsmallcelllungcanceraftertkitreatments AT jingyitang changesoftumormicroenvironmentinnonsmallcelllungcanceraftertkitreatments AT fenliu changesoftumormicroenvironmentinnonsmallcelllungcanceraftertkitreatments AT weili changesoftumormicroenvironmentinnonsmallcelllungcanceraftertkitreatments AT tingyan changesoftumormicroenvironmentinnonsmallcelllungcanceraftertkitreatments AT dangangshangguan changesoftumormicroenvironmentinnonsmallcelllungcanceraftertkitreatments AT nongyang changesoftumormicroenvironmentinnonsmallcelllungcanceraftertkitreatments AT dehualiao changesoftumormicroenvironmentinnonsmallcelllungcanceraftertkitreatments |